Orna Therapeutics

Orna’s acquisition of ReNAgade Therapeutics is a testament to our dedication to unlocking an entirely new and promising class of RNA-based medicines. Together, we are more than the sum of our platforms — with the potential to drive better efficacy and patient outcomes compared to current cell therapy and gene editing approaches — addressing massive unmet needs in diseases such as sickle cell and thalassemia. Read more here: https://lnkd.in/eYHYAfkf #RNA #Biotech #Biopharma

In case you missed this morning’s news, Orna acquired ReNAgade Therapeutics — a significant step forward for the field of RNA-targeted therapies and for modalities with continued unmet need including CAR therapy and gene editing. We are leveraging deep knowledge and a range of highly innovative capabilities to solve the most pressing challenges in drug development today.   Read more here: https://lnkd.in/eYHYAfkf #RNA #Biotech #Biopharma #Science

Today marks a new chapter for Orna and for the future of RNA-based medicines as we announce our acquisition of ReNAgade Therapeutics. This strategic move unifies two industry-leading circles with the knowhow to significantly expand circular RNA engineering and delivery technologies and advance in vivo CAR and gene editing approaches for a range of diseases. Join us in welcoming Amit Munshi as Chief Executive Officer as Tom Barnes, PhD transitions to Co-Chair of our Scientific Advisory Board. Read more here: https://lnkd.in/eYHYAfkf #Biopharma #Science #Biotech

Orna is Baltimore-bound! Be sure to catch us at #ASGCT2024, where we’ll present several posters highlighting our industry-leading circular RNA technology (oRNA). For more info: https://lnkd.in/dHgkVjV

Thank you Matthew Pillar and Anna Rose Welch for a great Business of Biotech conversation with our CEO Tom Barnes, covering the journey of an academic in biotech and the immense potential of circles in #RNA 🎧 Listen to the full conversation on your favorite podcast platform or on the website here:  https://lnkd.in/eT-qwEzt

What a wheel-y awesome night we had showing off our moves and bonding over some serious fun! Our #Ornacorns laced up and skated circles around the Chez-Vous Roller Skating Rink here in Boston. 🛼 From breakthroughs in the lab to breaking it down on the floor, let's keep the momentum going, on and off the rink!

We are excited to announce that Frank Neumann, M.D., Ph.D., will join the Orna team as Chief Medical Officer later this month. Dr. Neumann will bring deep industry expertise, spanning proof-of-concept to clinical evaluation and beyond, as we reshape RNA therapeutics to realize new treatment possibilities in hematological malignancies, autoimmune diseases and beyond. Read more: https://lnkd.in/eHrNuqUf

We are excited to announce that Frank Neumann, M.D., Ph.D., will join the Orna team as Chief Medical Officer later this month. Dr. Neumann will bring deep industry expertise, spanning proof-of-concept to clinical evaluation and beyond, as we reshape RNA therapeutics to realize new treatment possibilities in hematological malignancies, autoimmune diseases and beyond. Read more: https://lnkd.in/eHrNuqUf

Even though spring has sprung, we traded lab coats and circles for snow gear and diamond runs during Orna's Ski and Snowboard Day! #Ornacorns had a great time on the slopes at Loon Mountain in NH. ❄️

Being irrational can be fun sometimes - thank you so much to Petsi Pies and Frank Pepe's for the sweet and savory pies for our #Ornacorns on Pi Day!